Citations to this article

The adaptive stroma joining the antiangiogenic resistance front
Oriol Casanovas
Oriol Casanovas
Published March 23, 2011
Citation Information: J Clin Invest. 2011;121(4):1244-1247. https://doi.org/10.1172/JCI46430.
View: Text | PDF
Commentary

The adaptive stroma joining the antiangiogenic resistance front

Abstract

Resistance to antiangiogenic therapies in cancer involves both tumor cells and stromal components, but their relative contributions differ in each cancer subtype. In this issue of the JCI, Cascone et al. describe a stromal adaptation to antiangiogenic therapy in non–small cell lung carcinoma (NSCLC) models that include EGFR-driven vascular remodeling promoting resistance to VEGF inhibition. Their results suggest that the added benefit of dual VEGF/R and EGFR targeting in these models could be clinically relevant to fight resistance in NSCLC patients.

Authors

Oriol Casanovas

×

Total citations by year

Year: 2020 2017 2015 2012 Total
Citations: 2 1 1 2 6
Citation information

Citations to this article (6)

Title and authors Publication Year
Tumor Microenvironment: Recent Advances
A Birbrair 		2020
Angiocrine endothelium: from physiology to cancer
J Pasquier, P Ghiabi, L Chouchane, K Razzouk, S Rafii, A Rafii 		Journal of Translational Medicine 2020
The HGF/c-MET Pathway Is a Driver and Biomarker of VEGFR-inhibitor Resistance and Vascular Remodeling in Non–Small Cell Lung Cancer
T Cascone, L Xu, HY Lin, W Liu, HT Tran, Y Liu, K Howells, V Haddad, E Hanrahan, MB Nilsson, MA Cortez, U Giri, H Kadara, B Saigal, YY Park, W Peng, JS Lee, AJ Ryan, JM Jüergensmeier, RS Herbst, J Wang, RR Langley, II Wistuba, JJ Lee, JV Heymach 		Clinical cancer research 2017
Systems pharmacology approaches for optimization of antiangiogenic therapies: challenges and opportunities.
Sharan S, Woo S 		Frontiers in pharmacology 2015
Sox17 promotes tumor angiogenesis and destabilizes tumor vessels in mice
Hanseul Yang, Sungsu Lee, Seungjoo Lee, Kangsan Kim, Yeseul Yang, Jeong Hoon Kim, Ralf H. Adams, James Wells, Sean Morrison, Gou Young Koh, Injune Kim 		Journal of Clinical Investigation 2012
Activation of alternate prosurvival pathways accounts for acquired sunitinib resistance in U87MG glioma xenografts.
Zhou Q, Lv H, Mazloom AR, Xu H, Ma'ayan A, Gallo JM 		The Journal of pharmacology and experimental therapeutics 2012

Advertisement